Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

Tarkan Jäger; Matthias Ocker; Tobias Kiesslich; Elen Neureiter; Daniel Neureiter

doi:10.1080/13543784.2017.1274392

Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

Tarkan Jäger (Erstautor/-in)
, Matthias Ocker
, Tobias Kiesslich (Co-Autor/-in)
, Elen Neureiter
, Daniel Neureiter^* (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift › Editorial › Begutachtung

12 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	133-136
Fachzeitschrift	EXPERT OPINION ON INVESTIGATIONAL DRUGS
Jahrgang	26
Ausgabenummer	2
DOIs	https://doi.org/10.1080/13543784.2017.1274392
Publikationsstatus	Veröffentlicht - 2017

Zugriff auf Dokument

10.1080/13543784.2017.1274392

2 Abgeschlossen

A-12/02/006-KIE: ldentification of Novel Cancer Stem Cell-Related Drug Targets in Human Biliary Tract Cancer
Kiesslich, T. (Leitende(r) Forscher/-in) & Mayr, C. R. (Weitere Forschende)
13/11/12 → 13/03/14
Projekt: Forschung
Identification of Novel Cancer Stem Cell‐Related Drug Targets in Human Biliary Tract Cancer
Kiesslich, T. (Leitende(r) Forscher/-in)
1/09/12 → 1/09/15
Projekt: Forschung

Dieses zitieren

@article{556bfc753d7c4f23bfe453d02bcad177,

title = "Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.",

keywords = "BASAL-CELL CARCINOMA, MEDULLOBLASTOMA, VISMODEGIB, EFFICACY",

author = "Tarkan J{\"a}ger and Matthias Ocker and Tobias Kiesslich and Elen Neureiter and Daniel Neureiter",

note = "J{\"a}ger: Department of Surgery, Paracelsus Medical University, Salzburger Landeskliniken (SALK), Salzburg, Austria; Kiesslich: Department of Internal Medicine I, Paracelsus Medical University, Salzburger Landeskliniken (SALK), Salzburg, Austria; Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria; Neureiter: Institute of Pathology, Paracelsus Medical University, Salzburger Landeskliniken (SALK), Salzburg, Austria;",

year = "2017",

doi = "10.1080/13543784.2017.1274392",

language = "English",

volume = "26",

pages = "133--136",

journal = "EXPERT OPINION ON INVESTIGATIONAL DRUGS",

issn = "1354-3784",

number = "2",

}

TY - JOUR

T1 - Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

AU - Jäger, Tarkan

AU - Ocker, Matthias

AU - Kiesslich, Tobias

AU - Neureiter, Elen

AU - Neureiter, Daniel

N1 - Jäger: Department of Surgery, Paracelsus Medical University, Salzburger Landeskliniken (SALK), Salzburg, Austria; Kiesslich: Department of Internal Medicine I, Paracelsus Medical University, Salzburger Landeskliniken (SALK), Salzburg, Austria; Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria; Neureiter: Institute of Pathology, Paracelsus Medical University, Salzburger Landeskliniken (SALK), Salzburg, Austria;

PY - 2017

Y1 - 2017

KW - BASAL-CELL CARCINOMA

KW - MEDULLOBLASTOMA

KW - VISMODEGIB

KW - EFFICACY

U2 - 10.1080/13543784.2017.1274392

DO - 10.1080/13543784.2017.1274392

M3 - Editorial

C2 - 28004600

SN - 1354-3784

VL - 26

SP - 133

EP - 136

JO - EXPERT OPINION ON INVESTIGATIONAL DRUGS

JF - EXPERT OPINION ON INVESTIGATIONAL DRUGS

IS - 2

ER -

Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

Zugriff auf Dokument

Projekte

A-12/02/006-KIE: ldentification of Novel Cancer Stem Cell-Related Drug Targets in Human Biliary Tract Cancer

Identification of Novel Cancer Stem Cell‐Related Drug Targets in Human Biliary Tract Cancer

Dieses zitieren